

THE PATENT OFFICE IS HEREBY REQUESTED TO ACKNOWLEDGE RECEIPT  
OF THE FOLLOWING DOCUMENTS BY DATE STAMPING AND RETURNING  
THIS POST CARD

Serial No: 08/182,183

Applicant: Lin et al.

Filed: May 23, 1994

Examiner: Robert C. Hayes, Ph.D.

Art Unit: 1644

Title: Glial Cell Line-Derived Neurotrophic Factor

2 pgs Status Inquiry



S-225E  
DRC/khh

Via First Class Mail

March 29, 2001

Amgen Inc.  
One Amgen Center Drive  
Thousand Oaks, CA 91320-1799

**AMGEN**

Assistant Commissioner for Patents  
Washington, D.C. 20231

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Applicants:** Lin, *et al.*

**Group Art Unit:** 1644

**Serial No.:** 08/182,183

**Examiner:** Robert C. Hayes

**Filed:** May 23, 1994

**Docket No.:** SYNE-225-E

**For:** GLIAL CELL LINE-DERIVED  
NEUROTROPHIC FACTOR

**Date:** March 29, 2001

**STATUS LETTER**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In the Office Action dated June 15, 1999 (Paper No. 44) a shortened statutory period for response was set, ending September 15, 1999. The response was filed on July 9, 1999 within one (1) month of the Office Action. Our next document from the Patent Office was the Advisory Action of May 5, 2000. In a telephone conversation with the Examiner, the Examiner stated that prosecution of this case would be reopened to address the issues identified in the Advisory Action.


On August 15, 2000, Applicants filed an amendment and terminal disclaimer to address these last remaining issues identified by the Examiner. In a subsequent telephone conversation, the Examiner suggested that Applicants provide an additional draft discussion amendment for review by the Patent Office. That draft was sent for discussion on October 10, 2000.

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

March 29, 2001

Date

  
Signature

Applicants have received no further communication from the Patent and Trademark Office regarding this application. It would be appreciated if the Office would advise applicant(s) of the current status of this application.

Respectfully submitted,



Daniel R. Curry  
Attorney for Applicants  
Registration No: 32,727  
Phone: (805) 447-8102  
Date: March 29, 2001

Please send all future correspondence to:

U.S. Patent Operations/DRC  
Dept. 4300 M/S 27-4-A  
AMGEN INC.  
One Amgen Center Drive  
Thousand Oaks, California 91320-1799